gestonorone-caproate and Uterine-Neoplasms

Topics: Adult; Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Genital Neoplasms, Female; Gestonorone Caproate; Humans; Methotrexate; Middle Aged; Ovarian Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms; Vulvar Neoplasms

A pilot study with adjuvant hormone therapy in FIGO stage I endometrial carcinoma with myometrial invasion was carried out. All patients received total abdominal hysterectomy and bilateral salpingo-oophorectomy plus complementary radium therapy on the vaginal stump. After the conventional treatment, patients were randomly allocated to adjuvant hormone therapy or no further treatment. Hormone therapy consisted of gestonorone caproate (17 alpha-hydroxy-19-norpregn-4-en 3, 20 dione caproate) administered i.m. at the dose of 200 mg/week for 1 year. Of the 62 patients who entered the study, 51 were considered evaluable (24 with adjuvant hormone therapy and 27 with no further treatment). Five patients had a relapse: four of these were in the group with no further treatment. Actuarial relapse-free survival analysis at 5 years was 95.7% in the group of adjuvant-treated patients and 82.8% in the control group. Although there is no statistical significance, adjuvant therapy appears to result in an increase in relapse-free survival in the group of patients with deep myometrial invasion and undifferentiated carcinoma. Further studies are necessary to assess the effectiveness of hormone adjuvant treatment in FIGO stage I endometrial carcinoma with myometrial invasion.

Topics: Adenocarcinoma; Aged; Castration; Fallopian Tubes; Female; Gestonorone Caproate; Humans; Hysterectomy; Middle Aged; Pilot Projects; Radium; Uterine Neoplasms

Fifty-nine patients with proven stage I adenocarcinoma of the uterine corpus were treated by total abdominal hysterectomy and bilateral salpingo-oophorectomy, followed by gestronal hexanoate intramuscularly for 3 months and then medroxyprogesterone acetate orally for a prolonged period. In the 7-year period of study, there were no vaginal recurrences, but one patient suffered a recurrence in the inguinal lymph nodes and pelvis. Undesirable side effects did not occur. These results compare favourably with other reported studies in which surgery and radiotherapy were used.

Topics: Adenocarcinoma; Adult; Aged; Castration; Female; Gestonorone Caproate; Humans; Hysterectomy; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Postoperative Period; Recurrence; Uterine Neoplasms

Six human endometrial cancers in different clinical stages were xenotransplanted into thymusaplastic nude mice. Estrogen and progesterone receptors in the tumor tissue were determined in each case. Two carcinomas with both estrogen and progesterone receptors showed a better clinical course and grew more slowly in nude mice than the four carcinomas with no receptors at all. Treatment with the antiestrogen Tamoxifen in the carcinoma with positive estrogen receptors showed a significant growth retardation compared with the control group. Estrogen treatment gave accelerated growth, whereas gestagen treatment showed no significant effect. The progesterone receptor content of the receptor-positive tumor tissue might have been too small. None of the four receptor-negative carcinomas showed any influence of tumor growth during endocrine therapy. The results demonstrate the importance of receptor determination as a prognostic sign and, further, allow the endocrine therapy of endometrial carcinomas to be complemented with Tamoxifen in estrogen-receptor-positive tumor tissue.

Topics: Aged; Animals; Estradiol; Female; Gestonorone Caproate; Humans; Male; Medrogestone; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Receptors, Drug; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Uterine Neoplasms

Topics: Curettage; Dose-Response Relationship, Drug; Endometrium; Female; Gestonorone Caproate; Humans; Hysterectomy; Injections, Intramuscular; Mitosis; Uterine Neoplasms

Topics: Animals; Endometrium; Female; Gestonorone Caproate; Methylcholanthrene; Mice; Neoplasms, Experimental; Premedication; Uterine Neoplasms